Heat Biologics, Inc. (NASDAQ:HTBX) Downgraded by Zacks Investment Research
Heat Biologics, Inc. (NASDAQ:HTBX) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research note issued to investors on Wednesday.
According to Zacks, “Heat Biologics, Inc. is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of various cellular therapeutic vaccines for a range of cancers and infectious diseases. The Company’s products under development include HS-110 for the treatment of non-small cell lung cancer, HS-410 for the bladder cancer treatment, HS-310 to treat ovarian cancer and HS-510 for treating triple negative breast cancer. Heat Biologics, Inc. is based in Chapel Hill, North Carolina. “
Separately, Noble Financial restated a “buy” rating on shares of Heat Biologics in a research note on Tuesday, July 4th.
Heat Biologics (NASDAQ:HTBX) traded up 0.0182% during midday trading on Wednesday, reaching $0.5501. 274,955 shares of the company’s stock traded hands. Heat Biologics has a one year low of $0.54 and a one year high of $3.35. The stock’s market cap is $19.59 million. The stock’s 50 day moving average price is $0.67 and its 200-day moving average price is $0.82.
ILLEGAL ACTIVITY NOTICE: “Heat Biologics, Inc. (NASDAQ:HTBX) Downgraded by Zacks Investment Research” was posted by American Banking News and is owned by of American Banking News. If you are reading this news story on another domain, it was stolen and republished in violation of U.S. & international trademark & copyright law. The original version of this news story can be read at https://www.americanbankingnews.com/2017/07/12/heat-biologics-inc-nasdaqhtbx-downgraded-by-zacks-investment-research.html.
An institutional investor recently raised its position in Heat Biologics stock. KCG Holdings Inc. boosted its position in shares of Heat Biologics, Inc. (NASDAQ:HTBX) by 35.3% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 175,769 shares of the biopharmaceutical company’s stock after buying an additional 45,831 shares during the period. KCG Holdings Inc. owned about 0.52% of Heat Biologics worth $156,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 10.03% of the company’s stock.
Heat Biologics Company Profile
Heat Biologics, Inc is a development-stage company focused on developing allogeneic, off-the-shelf cellular therapeutic vaccines to combat a range of cancers. The Company is an immuno-oncology company, which focuses on T cell-stimulating platform technologies, such as Immune Pan-Antigen Cytotoxic Therapy (ImPACT) and Combination Pan-Antigen Cytotoxic Therapy (ComPACT).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Heat Biologics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heat Biologics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.